Literature DB >> 1976666

Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections.

M J Hepner1, D R Ownby, J A Anderson, M S Rowe, D Sears-Ewald, E B Brown.   

Abstract

To learn whether patients taking beta-blocker (BB) drugs were at increased risk of having systemic reactions (SRs) from allergen immunotherapy, we prospectively studied 56,105 injection visits in 3178 patients during a 1-year interval. A total of 166 SRs occurred in 144 patients (4.5% of all patients) or 3.0 SRs occurred per 1000 injection visits. Sixty-eight patients were taking BB drugs throughout the year, and only one patient had an SR. By chance, 3.08 patients were expected to have had SRs. We conclude that BB drugs did not increase the frequency of SRs in the patients studied who were receiving immunotherapy (p greater than 0.95). Patients taking BB drugs may still be at increased risk, however, from more severe SRs or their SRs may be more refractory to therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976666     DOI: 10.1016/s0091-6749(05)80105-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

1.  Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK)

Authors:  D Chamberlain
Journal:  J Accid Emerg Med       Date:  1999-07

Review 2.  Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?

Authors:  David M Lang
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

Review 3.  The risk and management of anaphylaxis in the setting of immunotherapy.

Authors:  Phil Lieberman
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

4.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

Review 5.  Fatalities following allergen immunotherapy.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 6.  Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers.

Authors:  D M Lang
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 7.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 8.  Exercise-induced Anaphylaxis.

Authors:  Mariana C Castells; Richard F Horan; Albert L Sheffer
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

9.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

Review 10.  [Hymenoptera venom anaphylaxis and cardiovascular disease].

Authors:  U R Müller
Journal:  Hautarzt       Date:  2008-03       Impact factor: 1.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.